Halozyme Therapeutics (HALO) to Release Quarterly Earnings on Tuesday

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) is expected to announce its earnings results after the market closes on Tuesday, February 18th. Analysts expect the company to announce earnings of $1.17 per share and revenue of $285.74 million for the quarter. Investors that wish to listen to the company's conference call can do so using this link.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO traded down $0.32 during trading on Friday, reaching $58.29. The stock had a trading volume of 1,000,407 shares, compared to its average volume of 1,263,674. Halozyme Therapeutics has a 52 week low of $35.23 and a 52 week high of $65.53. The business's 50-day moving average price is $52.50 and its 200 day moving average price is $54.50. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The stock has a market capitalization of $7.42 billion, a PE ratio of 19.30, a P/E/G ratio of 0.44 and a beta of 1.25.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Piper Sandler boosted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research report on Friday, January 10th. Wells Fargo & Company dropped their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. HC Wainwright restated a "buy" rating and issued a $70.00 price objective on shares of Halozyme Therapeutics in a research report on Tuesday, February 4th. JMP Securities boosted their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a research report on Friday, November 1st. Finally, Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $60.89.

Insider Activity

In related news, Director Jeffrey William Henderson sold 10,000 shares of the company's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now directly owns 43,611 shares of the company's stock, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.